Bio Pharma Dive
NOVEMBER 19, 2020
The deal, which has Pfizer paying as much as $70 million, is the latest in a series of moves by big pharma companies to forge a stronger position in the world's second-largest drug market.
World of DTC Marketing
NOVEMBER 19, 2020
People who stay with a company just because of their salary and benefits are not the kind of people that are needed to make the leap from good to great. This week a friend and colleague I have known for over ten years decided to leave her current position where she was a top performer for a position where her expertise would be more valued. No one tried to stop her from leaving or asked if there was anything they could do to keep her.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
NOVEMBER 20, 2020
Service also offers price comparison on generic and branded drugs
NY Times
NOVEMBER 18, 2020
The company said it planned to apply for emergency approval from the Food and Drug Administration “within days.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
NOVEMBER 17, 2020
The therapy's developer, Brainstorm Therapeutics, blamed the setback on better-than-expected results from placebo-treated patients. The biotech still sees a path forward, however.
World of DTC Marketing
NOVEMBER 17, 2020
SUMMARY : Searching for online health information has become more complicated and is often wrought with bad health information. Pharma product websites need to evolve and become a credible source of inline health information for people who are often lost in bad information online. Pharma product websites have always had one objective: get the website visitor to ask their doctor for an Rx.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioPharma Reporter
NOVEMBER 16, 2020
Johnson & Johnson has launched a second global Phase 3 trial for its Janssen COVID-19 vaccine candidate: this time exploring a 2-dose regimen (its existing Phase 3 trial explores a 1-dose regimen).
Bio Pharma Dive
NOVEMBER 19, 2020
The results are first to emerge from a late-stage test of a hemophilia B gene therapy, and show UniQure's treatment can restore clotting protein levels to mild or even near normal levels.
Pharma Mirror
NOVEMBER 18, 2020
CPhI & P-MEC China returns as a hybrid event in Shanghai (16-18 December 2020), with a physical exhibition running alongside Virtual Expo Connect (18 November – 18 December 2020)for international audiences unable to attend. The physical exhibition will be held at the SNIEC (Shanghai New International Expo Center), with some 3,000 exhibitors present across three days, alongside exhibitor talks and conferences.
Pharma Times
NOVEMBER 16, 2020
It is hoped that the move will help to tackle the persistent symptoms – such as fatigue and brain fog – suffered by people who have developed the condition
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
BioPharma Reporter
NOVEMBER 17, 2020
The future of treatment for many of the most challenging diseases in the world is said to reside in personalized cell and gene therapy (CGT). These expensive and complex therapies have proven highly effective in multiple cases, but a challenge remains around producing them at scale and at a reasonable cost.
Bio Pharma Dive
NOVEMBER 19, 2020
Facilities are preparing ultra-cold storage capabilities and reviewing secruity plans as they brace for their role in distributing potentially multiple shots.
NY Times
NOVEMBER 19, 2020
In a review of several trials, the World Health Organization found that Gilead’s drug did not improve survival rates for patients nor did it help them recover.
Pharma Times
NOVEMBER 17, 2020
MPs launch inquiry with view of securing extra support for sector
BioSpace
NOVEMBER 17, 2020
Immunotherapies are about to get safer, more effective, and even more accessible with the new biotech’s novel approach.
Bio Pharma Dive
NOVEMBER 16, 2020
Pharmacies and doctor's offices should be able to store Moderna's shot on site, a crucial advantage for the mass immunization challenge that lies ahead.
pharmaphorum
NOVEMBER 20, 2020
COVID-19 has turned the world on its head and healthcare systems have had to respond rapidly to match the sudden changes created by lockdown. Digital health had already been building a presence before the pandemic, but the tools it offers have been essential to counter the disruption caused by the coronavirus, reports Richard Staines. COVID-19 isn’t going away any time soon but when, and if, this crisis subsides the healthcare systems that are left behind will have changed radically.
Pharma Times
NOVEMBER 17, 2020
Drug combinations tested were found to be well tolerated
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioPharma Reporter
NOVEMBER 16, 2020
Modernaâs mRNA COVID-19 vaccine candidate has reported vaccine efficacy of 94.5% in the first Phase 3 interim analysis, released this morning. "This is a pivotal moment," says Moderna's CEO.
Bio Pharma Dive
NOVEMBER 20, 2020
The companies expect immunizations with their shot, if approved, could begin in high-risk groups by the middle to end of December.
pharmaphorum
NOVEMBER 20, 2020
Doctors in the US are to get another option to treat COVID-19 after the FDA granted an Emergency Use Authorization (EUA) for Eli Lilly’s baricitinib. Baricitinib is the active ingredient in Lilly’s rheumatoid arthritis drug Olumiant and is the latest example of a drug being repurposed to combat COVID-19. Most of the drugs attempt to tackle the inflammation that can cause complications in patients with severe disease.
Pharma Times
NOVEMBER 19, 2020
New findings from phase 2 study published in The Lancet
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
BioSpace
NOVEMBER 18, 2020
Researchers from the University of Birmingham, UK, announced today that they have developed a nasal spray that can potentially provide protection against COVID-19. Additionally, it is formulated using materials that have already been cleared for use in humans.
Bio Pharma Dive
NOVEMBER 16, 2020
Several effective vaccines will likely be needed to end the pandemic. Moderna's study results, which are equally strong as those reported by Pfizer and BioNTech last week, make that outcome more likely.
pharmaphorum
NOVEMBER 17, 2020
Pharmaceutical companies often struggle to actively involve patients in the design phase of clinical trials but doing so can have huge benefits for the sustainability and success of research. It can help address well established issues with studies, such as patient recruitment and retention, as well as reducing the need for additional trial protocol amendments.
Pharma Times
NOVEMBER 18, 2020
Designation is based on results from phase IIb/III HPTN 083 trial
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
BioSpace
NOVEMBER 16, 2020
Warren Buffett, one of America’s best-known investors, is backing multiple pharmaceutical companies developing therapies aimed at curbing the ongoing global COVID-19 pandemic.
Bio Pharma Dive
NOVEMBER 18, 2020
Reaching the main goal of their large trial, Pfizer and BioNTech reported 162 cases of COVID-19 among participants who received a placebo, and just 8 for those who were vaccinated.
XTalks
NOVEMBER 17, 2020
For the majority of fast-food restaurants, the only vegan items on the menu have tended to be the shredded lettuce and sliced tomatoes that topped a hamburger. That is, until now. Recently, the fast-food industry has embraced the growing demand for plant-based meat, with many popular chains beginning to offer vegan menu items that go beyond burger toppings.
Pharma Times
NOVEMBER 16, 2020
The funds will help expand the scale of SARS-CoV-2 virus sequencing in the hope of revealing new opportunities for intervention
Expert insights. Personalized for you.
364 
Let's personalize your content